[CAS NO. 475205-49-3]  A-317491

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [475205-49-3]

Catalog
HY-15568
Brand
MCE
CAS
475205-49-3

DESCRIPTION [475205-49-3]

Overview

MDLMFCD28044314
Molecular Weight565.57
Molecular FormulaC33H27NO8
SMILESO=C(C1=CC(C(N(CC2=CC=CC(OC3=CC=CC=C3)=C2)[C@H]4CCCC5=C4C=CC=C5)=O)=C(C(O)=O)C=C1C(O)=O)O

For research use only. We do not sell to patients.


Summary

A-317491 is a potent, selective and non-nucleotide antagonist of P2X 3 and P2X 2/3 receptors , with K i s of 22, 22, 9, and 92 nM for hP2X 3 , rP2X 3 , hP2X 2/3 , and rP2X 2/3 , respectively. A-317491 is highly selective ( IC50 >10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X 3 and P2X 2/3 receptor-mediated calcium flux [1] [2] .


IC50 & Target

Ki: 22 nM (hP2X3), 22 nM (rP2X3), 9 nM (hP2X2/3), 92 nM (rP2X2/3) [1]


In Vitro

A-317491 potently blocks recombinant human and rat P2X 3 and P2X 2/3 receptor-mediated calcium flux (K i =22-92 nM) [1] .
A-317491 (1 nM-10 μM) produces a concentration-dependent block of dorsal root ganglion (DRG) currents with an IC 50 of 15 nM [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

A-317491 (0.1-30 mg/kg; a single s.c.) dose-dependently reverses inflammatory mechanical hyperalgesia in rats [2] .
A-317491 (3-30 mg/kg; a single .v.) exhibits the plasma half-life (7.38 h), clearance rate (1.83 L/h/kg), and volume of distribution (0.17 L/kg) [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male adult Sprague-Dawley rats received an intraplantar injection of Freund's complete adjuvant [2]
Dosage: 0.1, 1, 3, 10, 30 mg/kg
Administration: A single s.c.
Result: Produced a dose-dependent reduction in mechanical hyperalgesia 1 h, 3 h and 5 h post-administration.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 47 mg/mL ( 83.10 mM )

H 2 O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7681 mL 8.8406 mL 17.6813 mL
5 mM 0.3536 mL 1.7681 mL 3.5363 mL
10 mM 0.1768 mL 0.8841 mL 1.7681 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (4.42 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.42 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.42 mM); Clear solution

* All of the co-solvents are available by MCE.